Clinicopathological impacts of c-Met overexpression in bladder cancer: evidence from 1,336 cases
Clinicopathological impacts of c-Met overexpression in bladder cancer: evidence from 1,336 cases
复制标题
c-Met 过度表达对膀胱癌的临床病理学影响：来自 1,336 例病例的证据
DOI：
10.2147/ott.s197540
复制
发表时间：
2019-01-01
影响因子：
4
通讯作者：
Zhu, Yi
中科院分区：
文献类型：
--
作者：
Xu, Xin;Zhang, Guanjun;Zhu, Yi
背景：多项研究研究了 c-Met 过度表达对膀胱癌的临床病理影响，但结果相互矛盾。我们进行了这项系统评价和荟萃分析，以评估 c-Met 状态在膀胱癌患者中的病理和预后作用。方法：从 PubMed 和中国知网（CNKI）数据库中检索并确定符合条件的研究（截至 2018 年 10 月 4 日）。 DerSimonian-Laird 随机效应模型用于计算汇总风险估计。结果：包括 1,336 例膀胱癌病例在内的 8 项研究最终被纳入本次荟萃分析。我们检测到与 c-Met 高表达相关的总生存期 (OS) 较差的风险显着增加（HR=2.42，95% CI 1.36–4.32）。 c-Met 状态与核分级（OR=0.82，95% CI 0.29–2.31）或肿瘤分期（OR=1.42，95% CI 0.41–4.89）之间没有关联。结论：本研究表明，原发癌组织中 c-Met 的过度表达与人类膀胱癌 OS 较差相关。然而，有必要使用标准化方法和标准进行更大规模的研究来验证这些发现。
Background: The clinicopathological impacts of c-Met overexpression in bladder cancer have been investigated in several studies with conflicting results. We performed this systematic review and meta-analysis to assess the pathologic and prognostic roles of c-Met status in bladder cancer patients. Methods: Eligible studies were searched and identified from the PubMed and China National Knowledge Infrastructure (CNKI) databases (up until October 4, 2018). The DerSimonian-Laird random-effects model was used to calculate the pooled risk estimates. Results: Eight studies including 1,336 bladder cancer cases were eventually included in this meta-analysis. We detected a significantly increased risk of poor overall survival (OS) associated with the high expression of c-Met (HR=2.42, 95% CI 1.36–4.32). There was no association between c-Met status and nuclear grade (OR=0.82, 95% CI 0.29–2.31) or tumor stage (OR=1.42, 95% CI 0.41–4.89). Conclusion: This study shows that the overexpression of c-Met in primary cancer tissues is associated with a worse OS in human bladder cancer. However, larger studies using standardized methods and criteria are warranted to verify these findings.